Amgen Inc. (AMGN), incorporated in 1980 and headquartered in Thousand Oaks, California, is a biotech titan that crafts ...

The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...

AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested ...

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

High-yield bargain opportunities exist for disciplined, value-focused investors. Read more about the two standout stocks I've ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

The biotech industry can be volatile even for relatively large companies. Amgen (NASDAQ: AMGN), one of the more prominent ...

Next-generation sequencing allows for critical insights into gene therapy products, which can help streamline and accelerate ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...